I3LUNG: Clinical Validation of a Multimodal AI Tool to Support Immunotherapy Decisions in NSCLC

Le résumé fourni par la source

Abstract Despite a decade of immunotherapy, treatment selection in non-small cell lung cancer (NSCLC) still relies on subgroup analyses and clinical scores. I3LUNG ( NCT05537922 ) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based trial, enrolling 2365 patients. We integrated real-world clinical data (RWD), computed tomography (CT) images, digital pathology (DP), and genomics (G) into machine learning early-fusion (MLEF) and deep-learning intermediate-fusion (DLIF) models. MLEF achieved consistent performance across outcomes (AUC≈0.74), with improved results in first-line patients (AUC up to 0.82). Multimodal models outperformed RWD in clinical-specific subgroups (AUCs up to 0.86). In the test set, AI models surpassed PD-L1, ECOG PS, NLR, LDH (all with p <0.01) and the LIPI score. The clinical usability study showed that expert and non-expert physicians could improve their prediction with the explainable AI (XAI) tool. The I3LUNG tool emerges as a clinically relevant decision-support system and is currently under prospective validation in >2,000 patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.